

Ivana Mikolasevic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2239235/publications.pdf>

Version: 2024-02-01

47
papers

1,251
citations

516710

16
h-index

377865

34
g-index

49
all docs

49
docs citations

49
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. <i>Medicina (Lithuania)</i> , 2022, 58, 252.	2.0	2
2	Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. <i>International Journal of Clinical Practice</i> , 2021, 75, e13770.	1.7	6
3	Nonalcoholic fatty liver disease â€“ a growing public health problem. <i>Croatian Medical Journal</i> , 2021, 62, 1-3.	0.7	5
4	Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	1.9	3
5	Small intestinal bacterial overgrowth and nonâ€“alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. <i>International Journal of Clinical Practice</i> , 2021, 75, e13947.	1.7	14
6	Fecal microbiota transplantation â€“ where are we?. <i>Croatian Medical Journal</i> , 2021, 62, 52-58.	0.7	1
7	Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-12.	1.9	2
8	Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature. <i>Current Drug Metabolism</i> , 2021, 22, 89-98.	1.2	2
9	Noninvasive markers of liver steatosis and fibrosis after liver transplantation â€“ Where do we stand?. <i>World Journal of Transplantation</i> , 2021, 11, 37-53.	1.6	7
10	Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	1.9	11
11	Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 428-437.	1.5	8
12	External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	1.9	2
13	Prevalence, predictors and ageâ€“related sexual and erectile dysfunction in patients with inflammatory bowel disease: A tertiary centre experience. <i>International Journal of Clinical Practice</i> , 2021, 75, e14486.	1.7	6
14	Non-Alcoholic Fatty Liver Disease and COVID-19â€“Two Pandemics Hitting at the Same Time. <i>Medicina (Lithuania)</i> , 2021, 57, 1057.	2.0	13
15	Role of Endoscopic Ultrasound in Liver Disease: Where Do We Stand?. <i>Diagnostics</i> , 2021, 11, 2021.	2.6	4
16	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.2	0
17	Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. <i>European Journal of Internal Medicine</i> , 2020, 82, 68-75.	2.2	22
18	Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-12.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Pre-existing liver disease in pregnancy: Cirrhosis, autoimmune hepatitis and liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 44-45, 101668.	2.4	7
20	Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2097-2106.	4.4	17
21	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-10.	1.9	40
22	Non-alcoholic fatty liver disease and transient elastography. <i>Exploration of Medicine</i> , 2020, 1, 205-217.	1.5	4
23	Vitamin D Deficiency: Consequence or Cause of Obesity?. <i>Medicina (Lithuania)</i> , 2019, 55, 541.	2.0	175
24	Prevention of Infectious Complications in Acute Pancreatitis. <i>Pancreas</i> , 2019, 48, 1056-1060.	1.1	11
25	Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study. <i>Croatian Medical Journal</i> , 2019, 60, 494-502.	0.7	9
26	Editorial Comment to Non-invasive assessment of kidney allograft fibrosis with shear wave elastography: A radiological-pathological correlation analysis. <i>International Journal of Urology</i> , 2018, 25, 456-456.	1.0	0
27	Liver Disease During Pregnancy: A Challenging Clinical Issue. <i>Medical Science Monitor</i> , 2018, 24, 4080-4090.	1.1	78
28	Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma – where do we stand?. <i>Croatian Medical Journal</i> , 2018, 59, 97-99.	0.7	6
29	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2018, 24, 1491-1506.	3.3	95
30	Endoscopic retrograde cholangiopancreatography-induced and non-endoscopic retrograde cholangiopancreatography-induced acute pancreatitis: Two distinct clinical and immunological entities?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2018, 10, 259-266.	1.2	2
31	Fatty liver allografts are associated with primary graft non-function and high mortality after transplantation. <i>Liver International</i> , 2017, 37, 1113-1115.	3.9	10
32	Transient elastography (FibroScan [®]) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2016, 22, 7236.	3.3	193
33	Nonalcoholic fatty liver disease - A multisystem disease?. <i>World Journal of Gastroenterology</i> , 2016, 22, 9488.	3.3	148
34	Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation. <i>Hepatology Research</i> , 2016, 46, 841-852.	3.4	16
35	Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1347-1353.	2.3	43
36	Nonalcoholic Fatty Liver Disease (NAFLD) – A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2016, 36, 427-432.	2.3	20

#	ARTICLE	IF	CITATIONS
37	Relationship between nonalcoholic fatty liver disease and MIA syndrome. Hemodialysis International, 2015, 19, 472-481.	0.9	5
38	Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Design, Development and Therapy, 2015, 9, 4835.	4.3	53
39	Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wiener Klinische Wochenschrift, 2015, 127, 355-362.	1.9	25
40	Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wiener Klinische Wochenschrift, 2015, 127, 451-458.	1.9	14
41	Clinical profile, natural history, and predictors of mortality in patients with acute-on-chronic liver failure (ACLF). Wiener Klinische Wochenschrift, 2015, 127, 283-289.	1.9	13
42	Nonalcoholic fatty liver disease (NAFLD) – a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. Clinical Interventions in Aging, 2014, 9, 1295.	2.9	27
43	Nonalcoholic Fatty Liver Disease (NAFLD) And Cardiovascular Risk In Renal Transplant Recipients. Kidney and Blood Pressure Research, 2014, 39, 308-314.	2.0	23
44	Non-Alcoholic Fatty Liver Disease Proven by Transient Elastography in Hemodialysis Patients: Is It a New Risk Factor for Adverse Cardiovascular Events?. Blood Purification, 2014, 37, 259-265.	1.8	18
45	Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. Wiener Klinische Wochenschrift, 2014, 126, 474-479.	1.9	13
46	Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease Proven by Transient Elastography. Kidney and Blood Pressure Research, 2013, 37, 305-310.	2.0	61
47	CTLA-4 +49 and TNF-alpha-308 gene polymorphisms in celiac patients with exocrine pancreatic insufficiency. Collegium Antropologicum, 2013, 37, 1191-4.	0.2	3